Better Therapeutics (BTTX) Stock Price, News & Analysis

Company Overview

Better Therapeutics, Inc. is a clinical-stage digital therapeutics company focused on developing prescription software-based treatments for cardiometabolic diseases. Its lead product candidate, BT-001, is a behavior-change program delivered via a smartphone application, designed to address underlying drivers of type 2 diabetes and hypertension through cognitive behavioral therapy techniques. The company’s platform is built to engage patients in personalized lifestyle modification, leveraging real-time feedback and data analytics to support sustained clinical improvements.

BT-001 is being evaluated in pivotal clinical trials under FDA investigational device exemptions, with studies examining its impact on glycemic control and blood pressure reduction. Better Therapeutics collaborates with academic research centers and healthcare providers to validate its therapeutic approach, aiming to secure FDA clearance as a prescription digital therapeutic. The company’s evidence-generation strategy includes randomized controlled trials and real-world evidence initiatives to demonstrate safety, efficacy and long-term adherence benefits.

Founded in 2016 and headquartered in Redwood City, California, Better Therapeutics operates primarily in the United States, with plans to expand its commercial and regulatory footprint internationally. The company is led by CEO Sean Duffy, who brings extensive experience in digital health innovation, and a management team comprised of professionals in clinical development, regulatory affairs and commercial strategy. Better Therapeutics has assembled a scientific advisory board featuring thought leaders in endocrinology, behavioral science and digital health.

Better Therapeutics aims to transform chronic disease management by providing scalable, evidence-based digital interventions that complement traditional medical therapies. Its mission is to empower patients and healthcare systems with tools that address root causes of cardiometabolic conditions, improve clinical outcomes and reduce long-term healthcare costs.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 15,239 shs
• Market Capitalization: $5 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BTTX Stock Analysis - Frequently Asked Questions

How do I buy shares of Better Therapeutics?

Shares of BTTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Better Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Better Therapeutics investors own include Predictive Oncology (POAI), Ford Motor (F), JPMorgan Chase & Co. (JPM), Cricut (CRCT), Zomedica (ZOM), Wells Fargo & Company (WFC) and Abbott Laboratories (ABT).

Company Calendar

• Today: 10/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Health services
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:BTTX
• CIK: 1832415
• Web: mcacquisition.com
• Phone: 415-887-2311
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 49,862,000
• Free Float: 24,233,000
• Market Cap: $5 thousand
• Optionable: Optionable
• Beta: 0.98